سعر اندوريستات 120مجم 20 قرص 2025

Film-coated tablets containing febuxostat 120 mg (Al Andalous Pharmaceutical Industries), a non-purine selective xanthine oxidase inhibitor that lowers serum uric acid; 20 tablets per pack.

• Chronic hyperuricaemia in conditions where urate deposition has already occurred (tophus and/or gouty arthritis)Population: AdultsEuropean Medicines Agency (EMA)
• Prevention and treatment of hyperuricaemia in adults undergoing chemotherapy for haematologic malignancies at intermediate to high risk of tumour lysis syndromePopulation: AdultsEuropean Medicines Agency (EMA)

• Common: gout flares, liver function abnormalities, diarrhoea, nausea, headache, dizziness, dyspnoea, rash, pruritus, arthralgia, myalgia, oedema and fatigue.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to febuxostat or any excipient.International label, same formulation · European Medicines Agency (EMA)

• Pre-existing major cardiovascular disease (e.g., myocardial infarction, stroke, unstable angina): a higher rate of CV death versus allopurinol was seen in the CARES study (not in FAST); use with caution and monitor.International label, same formulation · European Medicines Agency (EMA)
• Serious hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis and acute anaphylaxis; do not restart after serious hypersensitivity.International label, same formulation · European Medicines Agency (EMA)
• Do not start during an acute gout attack; flares may occur at initiation (mobilisation of urate). Not recommended with mercaptopurine/azathioprine; liver function test before starting and periodically; caution in thyroid disorders.International label, same formulation · European Medicines Agency (EMA)

• Mercaptopurine / azathioprineXanthine oxidase inhibition may increase their plasma concentrations and toxicity; combination not recommended - if unavoidable, reduce mercaptopurine/azathioprine to 20% or less of the previous dose and monitor.European Medicines Agency (EMA)

• Should not be used during pregnancy (potential risk for humans unknown; very limited data).International label, same formulation · European Medicines Agency (EMA)
• Should not be used while breast-feeding.International label, same formulation · European Medicines Agency (EMA)

• Febuxostat: 2-arylthiazole derivative that lowers serum uric acid by potent, selective, non-purine inhibition of xanthine oxidase (oxidised and reduced forms), which catalyses hypoxanthine to xanthine to uric acid (EU SmPC).